Reward Pathway in the Brain: Dopamine and Addiction (MCAT)

Opioid agonist therapy for opioid use disorder involves three main pharmacological approaches: methadone (full agonist with slow onset that saturates receptors and prevents withdrawal, available only through licensed dispensaries), buprenorphine (partial agonist with ceiling effect at ~24mg that cannot cause respiratory depression and is available by prescription), and naltrexone (antagonist requiring prior detoxification). These medications differ in their pharmacokinetics (onset rates based on route of administration and lipophilicity), pharmacodynamics (activation of opioid receptors), and receptor avidity (binding strength and displacement potential). All three are equally effective for treatment retention and mortality reduction when properly indicated.

This section covers pharmacological approaches to substance use disorders including: methadone as a long-acting oral opioid agonist for heroin detoxification; buprenorphine as a partial opioid agonist administered sublingually for maintenance therapy; naloxone as a short-acting opioid antagonist for acute overdose reversal; and naltrexone as a long-acting oral opioid antagonist for preventing relapse after detoxification. Additional agents include varenicline (nicotinic receptor partial agonist) and bupropion for smoking cessation.

Full agonists fully activate the mu opioid receptor—more you take, more effects you feel until respiratory depression and potential fatal overdose. Buprenorphine as a partial agonist has a ceiling effect making it safer: limits respiratory depression in opioid-tolerant individuals, is much safer when combined with benzodiazepines, and users do NOT feel euphoria associated with it. This means emotions and feelings masked by full agonist opioids may resurface when starting buprenorphine, potentially worsening untreated depression or anxiety—important to counsel patients about this expectation. Antagonists (naloxone and naltrexone) block the mu receptor and don't activate it at all. Critically, antagonists also block endogenous opioids that contribute to happiness, which is why they are not recommended as primary treatment for OUD.

Two main drug categories treat addiction: agonists and antagonists. Agonists bind to opioid receptors, producing some pleasure effects but with fewer harms than illicit drugs, reducing the user's desire to consume drugs. Metadone is the primary agonist used to replace heroin consumption. Antagonists bind to receptors but block them, preventing other substances from attaching and producing effects. They do not create pleasure but reduce drug-seeking behavior. Naltrexone is an example that has shown effectiveness in reducing alcohol consumption, though its efficacy for heroin treatment remains unproven. Understanding these mechanisms is essential for effective addiction treatment.

Drug addiction can be treated pharmacologically using agonists (substances that replicate the drug's effects without the high) or antagonists (substances that block the drug's effects). Agonists like methadone can help manage withdrawal symptoms, while antagonists can help break the cycle of addiction.

Addiction affects the prefrontal lobe, causing concrete thinking failure, decreased attention, perseverative speech, altered reasoning, behavioral passivity, and decreased ability to prioritize attention. It causes total loss of impulse control, uncontrolled aggression, inappropriate language, and loss of interpersonal sensitivity. Subcortical structures (amygdala, hippocampus, hypothalamus) are damaged, affecting emotion processing, memory, and hormonal regulation. These changes impair normal functioning and decision-making.

In addiction, the prefrontal cortex (the brain's decision-making center) becomes impaired, a condition called hypofrontality. This impairs the brain's ability to weigh choices and values correctly. When triggered, sensitized pathways fire up, creating cravings for relief and pleasure. Users become dependent on the behavior to feel normal, even when they intellectually recognize no benefits exist. This explains why addicts continue their behavior despite knowing the negative consequences.

In addiction, the frontal cortex's top-down control over behavior fails due to abnormal activity in the orbital frontal cortex and anterior cingulate cortex. This state, called hypofrontality, reduces the frontal cortex to a shadow of its former self. Prior commitments, memories of negative consequences, love for family, and knowledge of punishment become invisible to the addict. The normal top-down control simply fails, explaining loss of control and impaired decision-making.

Addiction causes permanent brain damage that affects logical thinking and decision-making capabilities. The prefrontal cortex, responsible for rational judgment, becomes impaired. Even when individuals consciously decide not to use substances, they fail to implement this decision in real-time situations. Research indicates that approximately 90% of individuals with addiction cannot find solutions to their problems, while only 10% can. This cognitive impairment creates a cycle where promises to quit are repeatedly broken.

The 11 DSM-5 TR criteria for substance use disorder include: (1) taking larger amounts over longer periods than intended, (2) persistent desire or unsuccessful efforts to cut down, (3) time spent obtaining or using, (4) craving/strong urge to use, (5) failure to fulfill obligations, (6) giving up important activities, (7) continued use despite interpersonal problems, (8) recurrent use in hazardous situations, (9) continued use despite physical/psychological problems, (10) tolerance, and (11) withdrawal. Criteria 1, 2, 6, 8, 9, 10, and 11 were originally dependence criteria; criteria 4, 5, and 8 were originally abuse criteria. Severity is mild (2-3 criteria), moderate (4-5), or severe (6+).

The DSM-5 classifies substance use disorders using 11 diagnostic criteria organized into four categories (impaired control, social impairment, risky use, and pharmacological criteria), requiring at least two symptoms within a 12-month period to diagnose, with severity levels (mild, moderate, severe) based on the number of symptoms met; unlike DSM-4 which separated substance abuse and dependence, DSM-5 merged them into a single spectrum disorder, removed the legal problems criterion due to cultural bias concerns, and added craving as a new symptom.

A substance use disorder is diagnosed based on four domains: (1) Risky use involving dangerous situations like driving under the influence; (2) Social impairment including loss of employment, damaged relationships, and reduced social engagement; (3) Pharmacological factors including tolerance (needing increasing amounts for the same effect) and withdrawal symptoms; (4) Impaired control over substance use despite negative consequences. These criteria help distinguish recreational use from clinical disorder.

To diagnose substance use disorder, a person must exhibit at least two of the following symptoms within a 12-month period: spending excessive time obtaining, using, or recovering from use; using greater amounts over longer periods than intended; inability to cut down or control use; craving the substance; failure to fulfill major role obligations at work, school, or home; giving up important activities; continued use despite problems; tolerance (diminished effect requiring more substance to achieve desired effect); withdrawal symptoms; using in risky situations; and using despite negative consequences.

The DSM-5 uses a clinical diagnosis approach for substance use disorders rather than biological tests. Diagnosis involves evaluating 12 criteria organized into the mnemonic 'Four R's and Four C's plus withdrawal and tolerance.' The Four R's include: Risk of bodily harm (using despite health consequences), Relationship problems (conflict with family/friends), Role failure (inability to fulfill responsibilities as parent, worker, student), and Repeated attempts to cut back (cognitive dissonance between wanting to stop and continuing use). The Four C's are: Loss of control (inability to control substance use despite wanting to), Compulsive use (spending excessive time obtaining and using substances), Continued use despite harm, and Cravings. Withdrawal symptoms and tolerance development are additional criteria. A diagnosis requires meeting at least two of these criteria.